Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
U.S. News & World Report expands evaluation of outcomes in cancer subspecialties

U.S. News & World Report expands evaluation of outcomes in cancer subspecialties

Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.
August 01, 2025
Vol.51 No.30
By Sara Willa Ernst
U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data

U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access

In a change in methodology, U.S. News & World Report has integrated Medicare Advantage data into the analyses for patient outcomes, creating a shift in rankings for specialties that include oncology.
July 19, 2024
Vol.50 No.29
By Matthew Bin Han Ong
Cancer hospital rankings shift as U.S. News favors clinical metrics over “reputation” scores amid broader boycott

Cancer hospital rankings shift as U.S. News favors clinical metrics over “reputation” scores amid broader boycott

At a glance, the 2023-24 U.S. News & World Report ranking for Best Hospitals for Cancer looks the way it always has—a list of premier institutions. You have to dig deeper to find changes in the way the closely watched  40-year-old ranking was put together and why these changes in methodology were made.
August 04, 2023
Vol.49 No.31
By Matthew Bin Han Ong

Trending Stories

  • U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
  • GOP-led Congress rejects Trump’s plans to gut medical research
    Senate bill gives NIH a $400 million raise
  • Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
    MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?
  • Cancer Research Institute announces 2025 recipients of cancer immunotherapy awards
  • FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
  • USPSTF doesn’t lean right or left—it’s about data, not politics

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2025 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation
Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account